Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
03:48:34 EST Sun 08 Feb 2026
Enter Symbol
or Name
USA
CA



Z:PTN - PALATIN TECHNOLOGIES INC - https://www.palatin.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
PTN - Z1.014.10·20.000.215.72-0.225-1.49.513138715.75  16.1443  15.4569.00  4.3316:10:04Nov 1315 min RT 2¢

Recent Trades - Last 10 of 387
Time ETExPriceChangeVolume
16:10:04Z15.72-0.331
16:10:04Z15.72-0.331
16:04:28Z15.72-0.331
15:59:50Z15.772-0.27890
15:59:40Z16.00-0.051
15:59:30Z16.00-0.055
15:59:05Z15.985-0.0656
15:58:52Z15.95-0.105
15:58:43Z15.95-0.104
15:58:34Z15.95-0.108

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-11-13 07:30U:PTNNews ReleasePalatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
2025-11-12 12:15U:PTNNews ReleasePalatin Technologies Announces Closing of Upsized $18.2 Million Public Offering with the Full Exercise of the Underwriters' Over-Allotment Option
2025-11-06 08:00U:PTNNews ReleasePalatin Presents Data at ObesityWeek(TM) 2025 Highlighting Promise of Melanocortin-Based Therapies for Obesity
2025-08-08 16:00U:PTNNews ReleasePalatin Announces 1-for-50 Reverse Stock Split
2025-05-14 07:30U:PTNNews ReleasePalatin Reports Fiscal Year 2025 Third Quarter Results and Business Update
2025-05-09 07:30U:PTNNews ReleasePalatin Presents Promising Preclinical Data on Melanocortin Agonists for Retinopathy at ARVO 2025
2025-05-08 22:19U:PTNNews ReleasePalatin Technologies Announces Closing of Reduced Public Offering
2025-05-08 16:30U:PTNNews ReleasePalatin Presents Breakthrough Symptom Resolution Data from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease at ARVO 2025
2025-05-07 20:26U:PTNNews ReleasePalatin Technologies Announces Transition to OTC Pink Following NYSE American Delisting Notice
2025-05-07 08:15U:PTNNews ReleasePalatin Expects $11.5 Million Financing to Cure NYSE American Delisting Notice
2025-05-07 08:00U:PTNNews ReleasePalatin Technologies Announces Pricing of up to $23 Million Public Offering
2025-05-05 07:30U:PTNNews ReleasePalatin Presents Promising Preclinical Data for Melanocortin Agonist PL9588 at ARVO 2025, Highlighting a Dual-Action Glaucoma Therapy
2025-04-29 07:30U:PTNNews ReleasePalatin Announces Breakthrough Symptom Resolution in Updated Analyses from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease
2025-04-17 07:30U:PTNNews ReleasePalatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide
2025-04-14 07:00U:PTNNews ReleasePalatin Appeals NYSE American Notice of Delisting
2025-04-10 16:01U:PTNNews ReleasePalatin Technologies, Inc. Announces Receipt of NYSE American Notice of Delisting and Intention to Appeal
2025-04-10 07:30U:PTNNews ReleasePalatin to Present Positive Phase 2b Data for Melanocortin Agonist in Diabetic Kidney Disease at the National Kidney Foundation Spring Meeting
2025-03-31 07:30U:PTNNews ReleasePalatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study
2025-03-28 07:30U:PTNNews ReleasePalatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177
2025-03-25 07:30U:PTNNews ReleasePalatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency